ArticleDiscover oncology2025
Fumarate hydratase in cancer research: scientific trends and findings over 22 years.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveFumarate hydratase (FH) is a key enzyme in the Krebs cycle and cellular energy metabolism, playing a crucial role in tumorigenesis. It is considered a prognostic, diagnostic, and therapeutic target for many types of cancer. Therefore, FH is a popular scientific subject in cancer research. The current study aimed to identify cancer research in the WoS database and examine studies conducted on FH molecules using bibliometric indicators.
methodsThe keywords "fumarate hydratase" OR fumarase" AND "cancer OR tumor OR neoplasm" were used to search the WoS database. This search was performed using abstracts, titles, and keywords. The "Article" and "Review" options were used to access the data of papers published between 2002 and March 2024.
resultsA total of 840 publications (616 articles and 224 reviews) were published by the end of March 2024. Research output on FH and cancer has significantly increased recently, with the highest number of publications in 2020 (n = 69, 8.214%). The most commonly used language was English (n = 823, 97.976%), and the USA led in productivity, contributing 306 studies (36.429%). The University of Helsinki is the most productive affiliation with 138 published articles. The researcher who conducted most studies (n = 58, 6.904%) was also the most-cited author, with 1562 citations. In the current bibliometric study, "hereditary leiomyomatosis", "mutations", and "renal-cell cancer" were frequently included in publications.
conclusionThis bibliometric study provides a quantitative overview of FH research in oncology and presents the most recent FH status in cancer research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.